Metraipolis › archive › dc_f2106778aea6

Comparative cost-effectiveness of sintilimab, toripalimab, and camrelizumab in first-line therapy for advanced non-squamous non-small cell lung cancer — Europe PMC PMID:41613047

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41613047
DOI
10.3389/fpubh.2025.1754642
License (as archived)
solo-consultazione
Archived
2026-11-06T19:49:30.537Z
SHA-256 of the archived text
5373eac0227864bde380d4528b30cf5d6e9873a5eac623833b64f61408fef2de
Stable URL of this page
https://metraipolis.com/documento/dc_f2106778aea6

How to cite

Comparative cost-effectiveness of sintilimab, toripalimab, and camrelizumab in first-line therapy for advanced non-squamous non-small cell lung cancer — Europe PMC PMID:41613047 — Europe PMC (en), https://europepmc.org/article/MED/41613047 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f2106778aea6 (Metraipolis archive dc_f2106778aea6, sha256 5373eac0227864bde380d4528b30cf5d6e9873a5eac623833b64f61408fef2de)
BibTeX
@misc{dcf2106778aea6,
  title = {Comparative cost-effectiveness of sintilimab, toripalimab, and camrelizumab in first-line therapy for advanced non-squamous non-small cell lung cancer — Europe PMC PMID:41613047},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41613047},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f2106778aea6; sha256 5373eac0227864bde380d4528b30cf5d6e9873a5eac623833b64f61408fef2de},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41613047. Agents can read the archived copy with the MCP tool read_document.